Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
about
Renal effects of dapagliflozin in patients with type 2 diabetesDiabetes DyslipidemiaTreatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directionsSodium-glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin-metforminPatient considerations in type 2 diabetes - role of combination dapagliflozin-metformin XREfficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitusCardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic MedicationsSodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetesAfter avandia: the use of antidiabetic drugs in patients with heart failureRenal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of actionSodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic ReviewSodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsUpdate on the treatment of type 2 diabetes mellitusSodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic AgentsSGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysisSodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A ReviewImpact of sodium-glucose cotransporter 2 inhibitors on blood pressureComparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysisBenefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-AnalysisEffect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal modelsDiabetic nephropathy - Epidemiology in Asia and the current state of treatmentEffects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 DiabetesThe management of type 2 diabetic patients with hypoglycaemic agentsThe role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment.Can you trust your animal study data?Sodium-Glucose linked transporter 2 (SGLT2) inhibitors--fighting diabetes from a new perspective.Patient Characteristics are not Associated with Clinically Important Differential Response to Dapagliflozin: a Staged Analysis of Phase 3 Data.Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.Sodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes.Efficacy and Safety of SGLT2 Inhibitors in Reducing Glycated Hemoglobin and Weight in Emirati Patients With Type 2 Diabetes.Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK.Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus.Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial.An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.Fasting plasma glucose and serum uric acid levels in a general Chinese population with normal glucose tolerance: A U-shaped curve.A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy
P2860
Q24564811-B6103DF6-9D1E-4CDC-A017-F09BC70709B8Q26750905-39D29640-25A1-4BB7-9B8B-1F00B418F3BBQ26751258-44B15DE5-625E-4940-BA97-10EB1906FCEDQ26752815-08E8AA1E-A665-4C61-B217-D92159CA5DE6Q26766404-A6EBA7BE-6DAA-4AC6-9CFC-91391D527104Q26782225-48576398-B754-4861-90DC-64D4060005D8Q26824616-30E1E26D-EADD-4E64-87F9-3985AD47B5CBQ26864336-5335289B-D813-4710-9F28-58E889F2D3E7Q27021166-0C5A6248-93C6-4BB9-8932-E7B85F47DC10Q27027105-D268A608-9D33-4386-9B44-609D89451E7EQ28072352-FEC3A210-F054-43FD-9CC2-B23132A0FDB5Q28072765-E8C0C85D-B7D1-4748-B3F1-37F70C2FD178Q28073342-1CB42354-D96F-499A-9375-15992BEAB68DQ28074843-D7B61231-42BB-48E3-BFF4-B79239D06764Q28076978-5E623477-1DEF-4FFA-BCB8-0D1DB27AF702Q28079134-8E022DBB-44AF-4AE2-A865-9B6C553C118BQ28080114-DA99D206-CCD1-4039-B6C2-A6922BE92192Q28546797-63B9B9D3-9135-4463-9215-F406B0892D1BQ28553482-F5AF0957-6A1B-43C8-93A7-017727BB6126Q28732080-1A990634-FF93-4F66-8278-2CBA0D008A89Q28742785-3A09C7BD-D55A-4C4F-8FE8-6AC87FC68A1BQ30248634-F73DFB71-0517-40AB-B90A-276B9F01857EQ30377441-1306A4A4-7F07-472C-8A9D-0B48D0161707Q30417363-F35BD5D1-2DC8-437C-8C9C-EC9A2F1E6FE3Q30663494-2280E984-2543-4FD2-81EE-6D0951158934Q30829341-AAE44D6D-3C34-4655-8838-8CC8F0A4A83FQ30833760-EDD6766A-25E3-4594-A078-0DAB60B0A414Q30877953-9C350229-C4AB-4917-B167-22B8FE82BDCEQ30903369-B237A8F6-2729-4C4C-AC51-5941CEC6FE7EQ33166813-6AD4F753-0C17-43D3-ABBA-4D391B35D479Q33451134-F50AE229-E6D9-4CE8-ABC3-623589650655Q33619161-79C07217-3ADA-46B0-BA18-06E83FC32713Q33625207-6251BDD4-1AED-42EF-9362-F66178668A38Q33732593-2374EEE0-B076-4099-A5B9-6151BBA24301Q33785128-48E50D5E-C248-41B9-9674-5C7DCF40003DQ33785136-EE0D95A1-FCC9-49E4-A639-22483A9D1F72Q33786150-8B394B82-2B7A-466D-BE09-C0E4F21FF880Q33802278-4036E6DD-77C2-452C-92E4-85DDFF01C1DCQ33848499-665F4448-B345-4C29-8F59-3DC598A0649CQ33859245-659EA6A5-4EFF-4245-8D64-066A8084B153
P2860
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Effect of dapagliflozin in pat ...... ind, placebo-controlled trial.
@en
Effect of dapagliflozin in pat ...... ind, placebo-controlled trial.
@nl
type
label
Effect of dapagliflozin in pat ...... ind, placebo-controlled trial.
@en
Effect of dapagliflozin in pat ...... ind, placebo-controlled trial.
@nl
prefLabel
Effect of dapagliflozin in pat ...... ind, placebo-controlled trial.
@en
Effect of dapagliflozin in pat ...... ind, placebo-controlled trial.
@nl
P2093
P921
P1433
P1476
Effect of dapagliflozin in pat ...... ind, placebo-controlled trial.
@en
P2093
Anne Pieters
Arnaud Bastien
James F List
Jorge L Gross
P304
P356
10.1016/S0140-6736(10)60407-2
P407
P577
2010-06-01T00:00:00Z